In this issue of JAMA, Montori and colleagues1 provide a valuable extensive and critical systemic review of clinical trials that were stopped early for benefit. Readers of the reports of such trials often feel a sense of excitement, especially when phrases such as “a major treatment advance,” “ethical need to stop the inferior treatment,” and “vital to tell the world immediately” are used. However, experience suggests that early results and enthusiasm, especially for modestly sized trials terminated early for apparent major benefit, are often moderated as subsequent reports arise.2
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 61
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.